Hee-je Y. Kim
Expertise in
16
conditions

Hee-je Y. Kim

Seoul St. Mary's Hospital, 
Seoul, KR 
Expertise in
16
conditions
Seoul St. Mary's Hospital, 
Seoul, KR 
OverviewLocationsClinical Research

Overview

Hee-je Kim practices in Seoul, Republic of Korea. Kim is highly rated in 16 conditions, according to our data. Their top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Splenectomy.

Their clinical research consists of co-authoring 316 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years.

Locations

Seoul St. Mary's Hospital, Seoul, Republic of Korea
Other Locations
Seoul St. Mary's Hospital, 222 Banpodaero, 06591, Seocho, Republic of Korea
Jeonju, 560011, Republic of Korea
St Mary's Hematology Hospital, Republic of Korea
Suwon, Republic of Korea
Busan, Republic of Korea
Incheon St. Mary's Hospital, Incheon, Republic of Korea
Jungnam, Republic of Korea
Daegu, Republic of Korea
Gyeonggi-do, Republic of Korea
Wondu, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3

315 Total Publications

Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/PTCy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia.
Feasibility of TBI-Augmented Reduced Toxicity Conditioning Regimen with ATG/PTCy Combination for Haploidentical Donor Transplantation in Adult Acute Lymphoblastic Leukemia.
Journal: Transplantation and cellular therapy
Published: February 21, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Kim's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile